SuperworthFreenome EPS FRNM
Diluted earnings per share by quarter and over the last twelve months, from 2024.
- Last 12 months, to Jun 30, 2026
- −$0.30
- Latest quarter, Q2 FY26
- −$0.01
- −114% on a year earlier
- Fiscal year 2025
- −$0.16
Freenome's earnings per share was −$0.30 over the twelve months to Jun 30, 2026, down 154% on a year earlier.
In its latest quarter, Q2 FY26, it was −$0.01, down 114% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.16 | n/a |
| FY2024 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.01 | −114% | −$0.30 | |
| Q1 FY26 | $0.00 | −100% | −$0.22 | |
| Q4 FY25 | −$0.30 | −188% | −$0.16 | |
| Q3 FY25 | $0.01 | −89% | $0.48 | |
| Q2 FY25 | $0.07 | +133% | $0.56 | |
| Q1 FY25 | $0.06 | n/a | $0.52 | |
| Q4 FY24 | $0.34 | n/a | n/a | |
| Q3 FY24 | $0.09 | n/a | n/a | |
| Q2 FY24 | $0.03 | n/a | n/a |
Against its peers
Companies in Healthcare nearest Freenome's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| FRNMFreenome | −$0.30 | −154% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| ICCCImmucell | $0.08 | −58% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ELMDElectromed | $1.31 | +56% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| UTMDUtah Medical Products | $3.28 | −12% a year |
| SPROSpero Therapeutics | $0.11 | |
| INFUInfuSystem | $0.41 | +78% a year |
| Peer median | $0.71 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Freenome
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.